Argenx said Thursday that Vyvgart, its top-selling drug, failed to outperform placebo in a Phase 3 trial of patients with Sjögren's disease — a rare late-stage setback for a company that has built one of the industry's strongest autoimmune development records.

The news moved markets immediately: Argenx shares slid 13% in Thursday-morning trading.

The trial targeted Sjögren's disease, a chronic autoimmune disorder. Argenx disclosed that Vyvgart did not beat placebo on the study's endpoints in this patient population, without detailing the full data in the announcement.

Why this miss stands out

Argenx has compiled a long run of clinical and commercial wins in autoimmune indications, a track record that helped it grow into one of the world's largest biotechs by market capitalization. For portfolio managers tracking the FcRn inhibitor class, the company has functioned as a near-benchmark for execution: successive approvals and label expansions had made late-stage failure an outlier scenario rather than an expected risk.

That context shapes how R&D leaders should read the result. A single Phase 3 miss in one indication does not undermine the drug's established uses, but it does mark the first public demonstration in years that Vyvgart's mechanism does not translate to every autoimmune target.

What the announcement did and did not include

Based on Argenx's Thursday statement:

• Vyvgart missed versus placebo in a Phase 3 Sjögren's disease trial.
• The company did not publicly detail effect sizes, patient numbers, or secondary endpoints in the initial disclosure.
• The 13% share decline followed the announcement the same morning.

Full trial data have not yet been presented in the public announcement, so any assessment of how close the drug came to significance — or whether a subgroup responded — awaits deeper disclosure, whether at a medical congress or in a peer-reviewed publication.

What this means for the Sjögren's field

Sjögren's disease remains one of the harder autoimmune indications to crack, and the failure adds a data point for any pipeline team weighing programs in the space. For companies with competing FcRn-targeting assets or other B-cell-directed mechanisms in Sjögren's, Argenx's miss will prompt a re-examination of assumptions about trial design, endpoint selection, and patient stratification in this population.

Analysts and clinicians will also watch whether Argenx clarifies whether it intends to continue pursuing the indication, pivot to a different trial design, or reallocate resources toward other pipeline programs — a decision that typically follows full data review.

The commercial backdrop

Vyvgart is Argenx's blockbuster franchise drug and the engine of its market valuation. A 13% single-day drop signals that investors had priced continued expansion success into the stock. The size of the decline also quantifies how much of the company's premium valuation rests on pipeline breadth rather than the already-approved label alone.

For biotech portfolio strategists, the episode is a reminder that even companies with high approval hit rates carry indication-specific risk, and that market caps built on expansion narratives reprice quickly when a Phase 3 reads out negative.

Further details of the trial results and Argenx's next steps for the Sjögren's program are expected as the company releases fuller data and updates its development plans.